IP Library Granted Patent US 9,889,203
Granted Patent B2
US 9,889,203 · App. 14/762,647 · Granted Feb 13, 2018

Chemical crosslinkers

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,889,203
App. No.
14/762,647
Granted
Feb 13, 2018
Kind
B2
Abstract

Disclosed herein are methods of chemical conjugation comprising contacting a lysosomal enzyme with a first crosslinking agent to introduce aldehyde groups; contacting a lysosomal targeting peptide with a second crosslinking agent to introduce a hydrazide group at the N-terminal residue; contacting the lysosomal enzyme with aldehyde groups of step a. with the lysosomal targeting peptide with a hydrazide group at the N-terminal residue of step b; and forming a lysosomal enzyme-lysosomal targeting peptide conjugate.

Claims (12)

1. A method of chemical conjugation comprising:

a. contacting a lysosomal enzyme with a first crosslinking agent to introduce aldehyde groups;

b. contacting a lysosomal targeting peptide with a second crosslinking agent to introduce a hydrazide group at the N-terminal residue;

c. contacting the lysosomal enzyme with aldehyde groups of a with the lysosomal targeting peptide with a hydrazide group at the N-terminal residue of b; and

d. forming a lysosomal enzyme-lysosomal targeting peptide conjugate.

2. The method of claim 1 wherein the lysosomal targeting peptide comprises variant insulin-like growth factor 2 (vIGF2) having the sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, or SEQ ID NO:4.

3. The method of claim 1 , wherein the first crosslinking agent comprises N-succinimidyl-4-formylbenzamide (S-4FB).

4. The method of claim 1 , wherein the second crosslinking agent comprises N-tert-butoxycarbonyl (tBoc)-protected hydrazide crosslinker (NHS-PEG4-tBoc-hydrazide).

5. The method of claim 1 , wherein the lysosomal enzyme comprises acid α-glucosidase (rhGAA), acid α-galactosidase A (GLA), acid β-glucuronidase (GUS), acid α-iduronidase A (IduA), acid iduronidate 2-sulfatase (I2S), β-hexosaminidase A (HexA), β-hexosaminidase B (HexB), acid α-mannosidase A, β-glucocerebrosidase (GlcCerase), acid lipase (LPA), or any combination thereof.

6. The method of claim 1 , wherein the lysosomal enzyme is human.

7. The method of claim 1 , wherein the lysosomal targeting peptide with a hydrazide group at the N-terminal residue is added in c at about four-fold molar excess.

8. The method of claim 1 , wherein aniline is added in c.

Assignments (4)
SECURITY INTEREST Recorded Apr 27, 2026
From: BIOMARIN PHARMACEUTICAL INC.; AMICUS THERAPEUTICS, INC.
To: CITIBANK, N.A., AS COLLATERAL AGENT
Reel/Frame 075493/0968 →
RELEASE OF SECURITY INTEREST Recorded Apr 27, 2026
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: AMICUS THERAPEUTICS, INC.
Reel/Frame 075494/0030 →
SECURITY INTEREST Recorded Oct 6, 2023
From: AMICUS THERAPEUTICS, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 065177/0196 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 22, 2015
From: DO, HUNG
To: AMICUS THERAPEUTICS, INC.
Reel/Frame 036154/0865 →